Cutler Investment Counsel LLC Purchases Shares of 176,676 Pfizer Inc. (NYSE:PFE)

Cutler Investment Counsel LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 176,676 shares of the biopharmaceutical company’s stock, valued at approximately $4,687,000.

A number of other large investors have also made changes to their positions in the business. Human Investing LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $85,000. KLCM Advisors Inc. increased its stake in Pfizer by 44.0% during the 4th quarter. KLCM Advisors Inc. now owns 189,694 shares of the biopharmaceutical company’s stock valued at $5,033,000 after purchasing an additional 57,984 shares in the last quarter. AlphaCentric Advisors LLC raised its holdings in shares of Pfizer by 10.9% in the fourth quarter. AlphaCentric Advisors LLC now owns 38,807 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 3,807 shares during the last quarter. Americana Partners LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $13,112,000. Finally, Financiere des Professionnels Fonds d investissement inc. grew its holdings in shares of Pfizer by 47.5% during the fourth quarter. Financiere des Professionnels Fonds d investissement inc. now owns 389,006 shares of the biopharmaceutical company’s stock valued at $10,320,000 after buying an additional 125,233 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PFE shares. Guggenheim restated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.50 on Monday. The business’s 50 day moving average price is $26.28 and its 200 day moving average price is $27.56. The company has a market cap of $144.48 billion, a price-to-earnings ratio of 18.08, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 EPS. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.75%. Pfizer’s dividend payout ratio is 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.